Q2 FY2026 EarningsQ2 FY26 results beat consensus across most key financial metrics: revenue reached $13.88M vs. $13.18M expected, and gross margin improved to 63.9% vs. 61.87% expected. The performance was primarily driven by a 28.1% YoY surge in Surgical Aesthetics revenue, fueled by the AYON launch and international generator sales. Net loss per share (GAAP) was -$0.07, outperforming the consensus estimate of -$0.08, while operational efficiency helped narrow the loss from operations to -$1.81M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Apyx Medical(APYX) the Revenue is 13.88 M (+22.08%), Beat estimate;the EBIT is -1.806 M (+29.84%), Beat estimate;the EPS is -0.07 (+22.22%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B22.08%
0.01B15.85%
+0.00B6.23%
EBITExceed expectations
-0.00B29.84%
-0.00B13.58%
+0.00B16.26%
EPSExceed expectations
-0.0722.22%
-0.0828.89%
+0.012013.33%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf